McDavid Stilwell

Net worth: 145 339 $ as of 2024-04-29

53 year

Health Technology

Consumer Services

Active connections

Name	Gender	Age	Linked companies	Collaboration
Mark Stolper	M	52	COHERUS BIOSCIENCES, INC.	3 years
Lee Newcomer	M	71	COHERUS BIOSCIENCES, INC.	2 years
Jill O'Donnell-Tormey	M	68	COHERUS BIOSCIENCES, INC.	2 years
Charles Newton	M	53	COHERUS BIOSCIENCES, INC.	2 years
Bryan Mcmichael	M	46	COHERUS BIOSCIENCES, INC.	3 years
Theresa M. LaVallee	M	57	COHERUS BIOSCIENCES, INC.	3 years
David Scharfstein	M	63	Harvard Business School	21 years
Michael Ryan	M	-	COHERUS BIOSCIENCES, INC.	1 years
Rosh Dias	M	-	COHERUS BIOSCIENCES, INC.	2 years
Paul Reider	M	55	COHERUS BIOSCIENCES, INC.	3 years
Richard L. Hameister	M	-	COHERUS BIOSCIENCES, INC.	3 years
Karen Kotz	F	-	COHERUS BIOSCIENCES, INC.	2 years

Connections Chart

Multi-company connection

Former connections

Name	Gender	Age	Linked companies	Collaboration
Thomas P. Lynch	M	57	OREXIGEN THERAPEUTICS, INC.	3 years
Eckard Weber	M	73	OREXIGEN THERAPEUTICS, INC.	14 years
Lota Zoth	F	64	OREXIGEN THERAPEUTICS, INC.	7 years
Wendy Dixon	M	68	OREXIGEN THERAPEUTICS, INC.	6 years
Alex Sloane	M	-	Harvard Business School	10 years
Aaron Michel	M	-	Harvard Business School	3 years
Vincent R. Anicetti	M	69	COHERUS BIOSCIENCES, INC.	7 years
David Endicott	M	58	OREXIGEN THERAPEUTICS, INC.	6 years
Monica Forbes	F	49	OREXIGEN THERAPEUTICS, INC.	4 years
Vladimir Vexler	M	66	COHERUS BIOSCIENCES, INC.	10 years
John Pontius	M	68	GTx, Inc. GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN.	13 years
Deborah Jorn	F	66	OREXIGEN THERAPEUTICS, INC.	2 years
Joseph Hagan	M	55	OREXIGEN THERAPEUTICS, INC.	6 years
Barrington John Albert Furr	M	80	GTx, Inc. GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN.	4 years
Mary Szela	F	60	COHERUS BIOSCIENCES, INC.	7 years
Michael Carter	M	86	GTx, Inc. GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN.	-
Jason Shackelford	M	48	GTx, Inc. GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN.	-
Thomas Cannell	M	62	OREXIGEN THERAPEUTICS, INC.	3 years
V. Lawlis	M	72	COHERUS BIOSCIENCES, INC.	7 years
Dan Turner	M	62	OREXIGEN THERAPEUTICS, INC.	7 years
James Dalton	M	61	GTx, Inc. GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN.	9 years
Robert Karr	M	75	GTx, Inc. GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN.	6 years
Jeffrey G. Hesselberg	M	65	GTx, Inc. GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN.	-
Heather Turner	F	51	OREXIGEN THERAPEUTICS, INC.	8 years
Kenneth Robinson	M	69	GTx, Inc. GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN.	-
Alan C. Mendelson	M	76	COHERUS BIOSCIENCES, INC.	-
James Healy	M	59	COHERUS BIOSCIENCES, INC.	8 years
Joseph Lacob	M	68	OREXIGEN THERAPEUTICS, INC.	8 years
Samuel R. Nussbaum	M	75	COHERUS BIOSCIENCES, INC.	3 years
Michael Powell	M	69	OREXIGEN THERAPEUTICS, INC.	8 years
Edis Jamyn	M	-	Harvard Business School	2 years
Joel M. Podolny	M	-	Harvard Business School	3 years
Jonathan T. Pastor	M	-	Harvard Business School	2 years
Yon Sog Choi	M	-	Harvard Business School	2 years
Marco Giberti	M	-	Harvard Business School	3 years
Allison Checchi	F	-	Harvard Business School	2 years
Emily johnson lambert	F	-	Harvard Business School	2 years
Lea Bajc	F	-	Harvard Business School	2 years
Leslie Feinzaig	F	-	Harvard Business School	2 years
Adam Said	M	40	Harvard Business School	2 years
Jose Valentin Pantangco	M	52	Harvard Business School	2 years
Vanessa Ann Bartram	F	-	Harvard Business School	2 years
Mina Pacheco Nazemi	F	-	Harvard Business School	2 years
Marc Herdegen	M	-	Harvard Business School	2 years
Sherrese Soares	F	47	Harvard Business School	2 years
Bobby J. Sheth	M	45	Harvard Business School	2 years
Stephanie Holden	F	-	Harvard Business School	2 years
David Dickason	M	-	GTx, Inc. GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN.	4 years
Morven Groves	F	-	Harvard Business School	2 years
Alexis DePree	F	45	Harvard Business School	2 years
Hector Gil	M	-	Harvard Business School	2 years
Aliceson Robinson	M	-	Harvard Business School	2 years
Nidhi Chadda	F	-	Harvard Business School	2 years
Srdjan Tanjga	M	-	Harvard Business School	2 years
David Salanic	M	-	Harvard Business School	2 years
Scott Alan Cullerton	M	-	Harvard Business School	2 years
Juan Enriquez	M	64	Harvard Business School	2 years
Christopher M. Busby	M	-	Harvard Business School	2 years
Marc André Novakoff	M	49	Harvard Business School	2 years
Brian Wayne Lemasters	M	-	Harvard Business School	2 years
Douglas Simmons	M	-	Harvard Business School	2 years
Jason Goins	M	-	Harvard Business School	2 years
Craig Stern	M	-	Harvard Business School	2 years
David Bordeau	M	-	Harvard Business School	2 years
David Matthew Friedman	M	-	Harvard Business School	2 years
Eliot E. Kerlin	M	50	Harvard Business School	2 years
Jill Catherine Raker	F	-	Harvard Business School	2 years
Fazeela A. Rashid	F	-	Harvard Business School	2 years
Benjamin A. Farkas	M	-	Harvard Business School	3 years
Danielle Hootnick	F	-	Harvard Business School	2 years
Jeff Swenson	M	48	Harvard Business School	2 years
John Doran	M	45	Harvard Business School	2 years
Jeremy A. Lynch	M	-	Harvard Business School	2 years
Edward Sobol	M	-	Harvard Business School	2 years
Alex Alvarez	M	-	Harvard Business School	2 years
Alex Kinnier	M	48	Harvard Business School	2 years
Nico Iacuzzi	M	-	Harvard Business School	2 years
Lee Rand	M	-	Harvard Business School	2 years
Laura Grattan	F	42	Harvard Business School	2 years
Min Zhang	F	50	Harvard Business School	2 years
So-Youn Song	M	-	Harvard Business School	2 years
Dong Hao Yang	M	52	Harvard Business School	2 years
Alex Popa	M	-	Harvard Business School	2 years
Özlem Tekay	F	-	Harvard Business School	4 years
Adam Dean Checchi	M	-	Harvard Business School	2 years
Samuel Clemens	M	-	Harvard Business School	2 years
Lily Surya	F	-	Harvard Business School	2 years

Statistics

Country	Connections	% of total
United States	99	100.00%

Age of Connections

Active

Past

Male

Female

Members of the board

Executives

Origin of connections